Balancing act: Safe and evidence-based prescribing for women of reproductive age

Lydia E. Pace, Eleanor Schwarz

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Teratogenic medications are commonly prescribed to women of reproductive age. Caring for women who may benefit from the use of teratogenic medications requires clinicians to engage patients in shared decision-making on the risks and benefits of medication use in the context of the patients fertility goals, the implications of the patients medical condition for a pregnancy and the risks and benefits of various contraceptive methods. Effective communication about all of these issues is essential to avoiding medication-induced birth defects. However, data suggest that such communication remains inadequate, leading some women to face unintentional exposure of a pregnancy to a teratogen, undesired pregnancy or, sometimes, the need for pregnancy termination services. This review outlines key information needed to ensure safe prescribing to women of childbearing age. It includes recommendations for changes in medical education, healthcare delivery and health policy to facilitate thoughtful prescribing and comprehensive care.

Original languageEnglish (US)
Pages (from-to)415-425
Number of pages11
JournalWomen's Health
Volume8
Issue number4
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Pregnancy
Communication
Teratogens
Health Policy
Medical Education
Contraception
Fertility
Decision Making
Delivery of Health Care

Keywords

  • birth defects
  • contraception
  • contraceptive counseling
  • preconception care
  • pregnancy
  • teratogenic medications

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Balancing act : Safe and evidence-based prescribing for women of reproductive age. / Pace, Lydia E.; Schwarz, Eleanor.

In: Women's Health, Vol. 8, No. 4, 01.07.2012, p. 415-425.

Research output: Contribution to journalReview article

@article{777db0cd0b414cf4b8875a9a4e90cb6c,
title = "Balancing act: Safe and evidence-based prescribing for women of reproductive age",
abstract = "Teratogenic medications are commonly prescribed to women of reproductive age. Caring for women who may benefit from the use of teratogenic medications requires clinicians to engage patients in shared decision-making on the risks and benefits of medication use in the context of the patients fertility goals, the implications of the patients medical condition for a pregnancy and the risks and benefits of various contraceptive methods. Effective communication about all of these issues is essential to avoiding medication-induced birth defects. However, data suggest that such communication remains inadequate, leading some women to face unintentional exposure of a pregnancy to a teratogen, undesired pregnancy or, sometimes, the need for pregnancy termination services. This review outlines key information needed to ensure safe prescribing to women of childbearing age. It includes recommendations for changes in medical education, healthcare delivery and health policy to facilitate thoughtful prescribing and comprehensive care.",
keywords = "birth defects, contraception, contraceptive counseling, preconception care, pregnancy, teratogenic medications",
author = "Pace, {Lydia E.} and Eleanor Schwarz",
year = "2012",
month = "7",
day = "1",
doi = "10.2217/whe.12.25",
language = "English (US)",
volume = "8",
pages = "415--425",
journal = "Women's health (London, England)",
issn = "1745-5057",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Balancing act

T2 - Safe and evidence-based prescribing for women of reproductive age

AU - Pace, Lydia E.

AU - Schwarz, Eleanor

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Teratogenic medications are commonly prescribed to women of reproductive age. Caring for women who may benefit from the use of teratogenic medications requires clinicians to engage patients in shared decision-making on the risks and benefits of medication use in the context of the patients fertility goals, the implications of the patients medical condition for a pregnancy and the risks and benefits of various contraceptive methods. Effective communication about all of these issues is essential to avoiding medication-induced birth defects. However, data suggest that such communication remains inadequate, leading some women to face unintentional exposure of a pregnancy to a teratogen, undesired pregnancy or, sometimes, the need for pregnancy termination services. This review outlines key information needed to ensure safe prescribing to women of childbearing age. It includes recommendations for changes in medical education, healthcare delivery and health policy to facilitate thoughtful prescribing and comprehensive care.

AB - Teratogenic medications are commonly prescribed to women of reproductive age. Caring for women who may benefit from the use of teratogenic medications requires clinicians to engage patients in shared decision-making on the risks and benefits of medication use in the context of the patients fertility goals, the implications of the patients medical condition for a pregnancy and the risks and benefits of various contraceptive methods. Effective communication about all of these issues is essential to avoiding medication-induced birth defects. However, data suggest that such communication remains inadequate, leading some women to face unintentional exposure of a pregnancy to a teratogen, undesired pregnancy or, sometimes, the need for pregnancy termination services. This review outlines key information needed to ensure safe prescribing to women of childbearing age. It includes recommendations for changes in medical education, healthcare delivery and health policy to facilitate thoughtful prescribing and comprehensive care.

KW - birth defects

KW - contraception

KW - contraceptive counseling

KW - preconception care

KW - pregnancy

KW - teratogenic medications

UR - http://www.scopus.com/inward/record.url?scp=84863601316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863601316&partnerID=8YFLogxK

U2 - 10.2217/whe.12.25

DO - 10.2217/whe.12.25

M3 - Review article

C2 - 22757732

AN - SCOPUS:84863601316

VL - 8

SP - 415

EP - 425

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5057

IS - 4

ER -